Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma

Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and su...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Ni, Zhang, Lu, Xu, Xiaoping, Chen, Bobin, Zhu, Chen, Li, Pei, Chen, Zi, Ding, Tianling, Ma, Yan, Yuan, Yan, Lin, Zhiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581143/
https://www.ncbi.nlm.nih.gov/pubmed/28881844
http://dx.doi.org/10.18632/oncotarget.15899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581143/
https://www.ncbi.nlm.nih.gov/pubmed/28881844
http://dx.doi.org/10.18632/oncotarget.15899

Ejemplares similares